
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc is positioned favorably due to its innovative drug pipeline targeting unmet medical needs in oncology and COVID-19, particularly with products like Endoxifen for breast cancer and AT-H201 and AT-301 for COVID-19 treatment. The company presents an attractive current valuation, as indicated by positive net present value (NPV) assessments, which suggest significant upside potential relative to its current share price. Furthermore, anticipated key clinical milestones and data releases are expected to serve as strong catalysts for stock performance, reinforcing optimism among analysts.
Bears say
Atossa Therapeutics Inc reported a net loss of $8.7 million, an earnings per share (EPS) of $(0.07), which aligns with previous estimates but raises concerns given the company's consistent inability to improve financial performance over multiple reporting periods. The financial outlook is further compounded by significant risks including balance sheet and liquidity challenges, potential failures in clinical trials, and uncertainties surrounding regulatory approvals and commercialization efforts. Additionally, external factors such as competition, macroeconomic changes, and fluctuating investor sentiment in the biotech sector contribute to a negative outlook for the company's stock performance.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares